Long-term effectiveness of zoledronic acid in patients with Paget's disease of bone - a retrospective cohort study.
Bisphosphonates
Osteitis deformans
Paget’s disease
Treatment
Zoledronic acid
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
30 Mar 2024
30 Mar 2024
Historique:
received:
31
12
2023
accepted:
18
03
2024
medline:
31
3
2024
pubmed:
31
3
2024
entrez:
30
3
2024
Statut:
aheadofprint
Résumé
The aims of the current study were to describe clinical and biochemical features of patients with Paget disease of bone (PDB) followed at our medical center, and to examine the long-term effectiveness of zoledronate. Retrospective cohort study included consecutive patients≥18 years with a diagnosis of PDB, followed in the Rabin Medical Center (RMC) Institute of Endocrinology from 1973 to 2023. The cohort comprised two groups: patients treated/not treated with zoledronic acid (ZOL/NZOL). The primary outcome was the percentage of patients who achieved a biochemical therapeutic response. Overall, 101 patients with PDB were included, 68 in the ZOL group and 33 in the NZOL group. The mean age was 65.2 ± 10.0 years, and 47% were female. Notably, 77% exhibited monostotic involvement, and only 3% had experienced fractures attributed to PDB. Mean ALP level at diagnosis was 160 ± 70.6 U/L. The median follow-up duration was 17 years since PDB diagnosis, comparable between the groups. Primary outcome was more prevalent in the ZOL compared to the NZOL group [42 patients (88%) VS 11 patients (52%) respectively, P = 0.004]. At the end of follow-up, mean ALP levels in the NZOL group were significantly higher than the levels in the ZOL group irrespective of the number of infusions received. The majority of patients with PDB experience a mild disease course, marked by monostotic involvement and a low prevalence of fractures. Zoledronic acid effectively manages PDB, providing sustained biochemical response. The necessity for multiple zoledronic acid injections remains questionable, often implemented due to osteoporosis.
Identifiants
pubmed: 38555314
doi: 10.1007/s12020-024-03791-7
pii: 10.1007/s12020-024-03791-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
M. Davie, M. Davies, R. Francis, W. Fraser, D. Hosking, R. Tansley, Paget’s disease of bone: a review of 889 patients. Bone 24(5), 11S–12S (1999). https://doi.org/10.1016/S8756-3282(99)00027-7
doi: 10.1016/S8756-3282(99)00027-7
pubmed: 10321918
R.D. Altman, D.A. Bloch, M.C. Hochberg, W.A. Murphy, Prevalence of pelvic Paget’s disease of bone in the United States. J. Bone Min. Res 15(3), 461–465 (2010). https://doi.org/10.1359/jbmr.2000.15.3.461
doi: 10.1359/jbmr.2000.15.3.461
C. Cooper, K. Schafheutle, E. Dennison, S. Kellingray, P. Guyer, D. Barker, The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J. Bone Min. Res 14(2), 192–197 (1999). https://doi.org/10.1359/jbmr.1999.14.2.192
doi: 10.1359/jbmr.1999.14.2.192
E. Gendron, F. Bouchard, N. Singbo, J.P. Brown, L. Michou, Decline in clinical severity of Paget’s disease of bone: comparison between a contemporary cohort and a historical cohort. Bone 170, 116721 (2023). https://doi.org/10.1016/j.bone.2023.116721
doi: 10.1016/j.bone.2023.116721
pubmed: 36858336
A.A. Morales-Piga, F.J. Bachiller-Corral, V. Abraira, J. Beltrán, A. Rapado, Is clinical expressiveness of Paget’s disease of bone decreasing? Bone 30(2), 399–403 (2002). https://doi.org/10.1016/S8756-3282(01)00674-3
doi: 10.1016/S8756-3282(01)00674-3
pubmed: 11856648
C. Britton, S. Brown, L. Ward, S.L. Rea, T. Ratajczak, J.P. Walsh, The changing presentation of Paget’s disease of bone in Australia, a high prevalence region. Calcif. Tissue Int 101(6), 564–569 (2017). https://doi.org/10.1007/s00223-017-0312-1
doi: 10.1007/s00223-017-0312-1
pubmed: 28884211
R.D. Tiegs, C.M. Lohse, P.C. Wollan, L.J. Melton, Long-term trends in the incidence of Paget’s disease of bone. Bone 27(3), 423–427 (2000). https://doi.org/10.1016/S8756-3282(00)00333-1
doi: 10.1016/S8756-3282(00)00333-1
pubmed: 10962355
S.H. Ralston, L. Corral-Gudino, C. Cooper, R.M. Francis, W.D. Fraser, L. Gennari, N. Guañabens, M.K. Javaid, R. Layfield, T.W. O’Neill, R.G.G. Russell, M.D. Stone, K. Simpson, D. Wilkinson, R. Wills, M.C. Zillikens, S.P. Tuck, Diagnosis and management of Paget’s disease of bone in adults: a clinical guideline: diagnosis and management of Paget’s disease of bone. J. Bone Min. Res 34(4), e3657 (2019). https://doi.org/10.1002/jbmr.3657
doi: 10.1002/jbmr.3657
F.R. Singer, H.G. Bone, D.J. Hosking, K.W. Lyles, M.H. Murad, I.R. Reid, E.S. Siris; Endocrine Society, Paget’s disease of bone: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(12), 4408–4422 (2014). https://doi.org/10.1210/jc.2014-2910
doi: 10.1210/jc.2014-2910
pubmed: 25406796
J.P. Lavender, I.M.A. Evans, R. Arnot, S. Bowring, F.H. Doyle, G.F. Joplin, I. MacIntyre, A comparison of radiography and radioisotope scanning in the detection of Paget’s disease and in the assessment of response to human calcitonin. BJR 50(592), 243–250 (1977). https://doi.org/10.1259/0007-1285-50-592-243
doi: 10.1259/0007-1285-50-592-243
pubmed: 870130
I.R. Reid, G.C. Nicholson, R.S. Weinstein, D.J. Hosking, T. Cundy, M.A. Kotowicz, W.A. Murphy, S. Yeap, S. Dufresne, A. Lombardi, T.A. Musliner, D.E. Thompson, A. John Yates, Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am. J. Med. 101(4), 341–348 (1996). https://doi.org/10.1016/S0002-9343(96)00227-6
doi: 10.1016/S0002-9343(96)00227-6
pubmed: 8873503
P.D. Miller, J.P. Brown, E.S. Siris, M.S. Hoseyni, D.W. Axelrod, P.J. Bekker, A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am. J. Med. 106(5), 513–520 (1999). https://doi.org/10.1016/S0002-9343(99)00062-5
doi: 10.1016/S0002-9343(99)00062-5
pubmed: 10335722
J.P. Walsh, L.C. Ward, G.O. Stewart, R.K. Will, R.A. Criddle, R.L. Prince, B.G.A. Stuckey, S.S. Dhaliwal, C.I. Bhagat, R.W. Retallack, G.N. Kent, P.J. Drury, S. Vasikaran, D.H. Gutteridge, A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone 34(4), 747–754 (2004). https://doi.org/10.1016/j.bone.2003.12.011
doi: 10.1016/j.bone.2003.12.011
pubmed: 15050907
I.R. Reid, P. Miller, K. Lyles, W. Fraser, J.P. Brown, Y. Saidi, P. Mesenbrink, G. Su, J. Pak, K. Zelenakas, M. Luchi, P. Richardson, D. Hosking, Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med 353(9), 898–908 (2005). https://doi.org/10.1056/NEJMoa044241
doi: 10.1056/NEJMoa044241
pubmed: 16135834
I.R. Reid, K. Lyles, G. Su, J.P. Brown, J.P. Walsh, J. del Pino-Montes, P.D. Miller, W.D. Fraser, S. Cafoncelli, C. Bucci-Rechtweg, D.J. Hosking, A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J. Bone Min. Res 26(9), 2261–2270 (2011). https://doi.org/10.1002/jbmr.438
doi: 10.1002/jbmr.438
D. Merlotti, L. Gennari, G. Martini, F. Valleggi, V. De Paola, A. Avanzati, R. Nuti, Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J. Bone Min. Res 22(10), 1510–1517 (2007). https://doi.org/10.1359/jbmr.070704
doi: 10.1359/jbmr.070704
D. Hosking, K. Lyles, J.P. Brown, W.D. Fraser, P. Miller, M.D. Curiel, J.-P. Devogelaer, M. Hooper, G. Su, K. Zelenakas, J. Pak, T. Fashola, Y. Saidi, E.F. Eriksen, I.R. Reid, Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J. Bone Min. Res 22(1), 142–148 (2007). https://doi.org/10.1359/jbmr.061001
doi: 10.1359/jbmr.061001
A. Tan, S.H. Ralston, Clinical presentation of Paget’s disease: evaluation of a contemporary cohort and systematic review. Calcif. Tissue Int 95(5), 385–392 (2014). https://doi.org/10.1007/s00223-014-9904-1
doi: 10.1007/s00223-014-9904-1
pubmed: 25160936
M. Barale, S. Sigrist, F. Bioletto, F. Maiorino, E. Ghigo, R. Mazzetti, M. Procopio, Long-term efficacy of intensive zoledronate therapy and predictors of retreatment in Paget’s disease of bone. Calcif. Tissue Int 109(4), 383–392 (2021). https://doi.org/10.1007/s00223-021-00848-x
doi: 10.1007/s00223-021-00848-x
pubmed: 33876253
pmcid: 8429167
A.L. Langston, M.K. Campbell, W.D. Fraser, G.S. MacLennan, P.L. Selby, S.H. Ralston, Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J. Bone Min. Res 25(1), 20–31 (2010). https://doi.org/10.1359/jbmr.090709
doi: 10.1359/jbmr.090709
A. Tan, K. Goodman, A. Walker, J. Hudson, G.S. MacLennan, P.L. Selby, W.D. Fraser, S.H. Ralston; for the PRISM-EZ Trial Group, Long-term randomized trial of intensive versus symptomatic management in Paget’s disease of bone: the PRISM-EZ study: intensive bisphosphonate therapy in Paget’s disease of bone. J. Bone Min. Res 32(6), 1165–1173 (2017). https://doi.org/10.1002/jbmr.3066
doi: 10.1002/jbmr.3066
T. Cundy, K. Maslowski, A. Grey, I.R. Reid, Durability of response to zoledronate treatment and competing mortality in Paget’s disease of bone. J. Bone Min. Res 32(4), 753–756 (2017). https://doi.org/10.1002/jbmr.3029
doi: 10.1002/jbmr.3029
I.R. Reid, J.P. Brown, N. Levitt, J.A. Román Ivorra, J. Bachiller-Corral, I.L. Ross, G. Su, O. Antunez-Flores, R.P. Aftring, Re-treatment of relapsed Paget’s disease of bone with zoledronic acid: results from an open-label study. Bonekey Rep. 2, 442 (2013). https://doi.org/10.1038/bonekey.2013.176
doi: 10.1038/bonekey.2013.176
pubmed: 24422139
pmcid: 3844974